Curis, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRIS research report →
Companywww.curis.com
Curis, Inc. , a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
- CEO
- James E. Dentzer
- IPO
- 2000
- Employees
- 34
- HQ
- Lexington, MA, US
Price Chart
Valuation
- Market Cap
- $6.50M
- P/E
- -4.52
- P/S
- 0.92
- P/B
- 7.52
- EV/EBITDA
- 0.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.45%
- Op Margin
- -485.12%
- Net Margin
- -299.66%
- ROE
- 805.67%
- ROIC
- -259.95%
Growth & Income
- Revenue
- $9.44M · -13.43%
- Net Income
- $-7,582,000 · 82.53%
- EPS
- $-0.58 · 91.57%
- Op Income
- $-32,902,000
- FCF YoY
- 31.25%
Performance & Tape
- 52W High
- $3.13
- 52W Low
- $0.46
- 50D MA
- $0.63
- 200D MA
- $1.16
- Beta
- 3.06
- Avg Volume
- 423.04K
Get TickerSpark's AI analysis on CRIS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | KAITIN KENNETH I | buy | 10,000 |
| Mar 20, 26 | Zung Jonathan B. | other | 66,667 |
| Mar 20, 26 | Zung Jonathan B. | other | 50 |
| Mar 20, 26 | Hamdy Ahmed MD | other | 66,667 |
| Mar 20, 26 | Hamdy Ahmed MD | other | 50 |
| Mar 20, 26 | Duvall Diantha | other | 66,666 |
| Mar 20, 26 | Duvall Diantha | other | 50 |
| Mar 20, 26 | Dentzer James E | other | 133,333 |
| Mar 20, 26 | Dentzer James E | other | 100 |
| Mar 20, 26 | Rubin Marc | other | 26,667 |
Our CRIS Coverage
We haven't published any research on CRIS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRIS Report →